Current Report Filing (8-k)
May 15 2017 - 5:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of Report
(Date of earliest event reported): May 15, 2017
THRESHOLD PHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-32979
|
|
94-3409596
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
170 Harbor Way, Suite 300
|
South San Francisco, California 94080
|
(Address of principal executive offices, including zip code)
|
(650) 474-8200
(Registrant’s telephone number, including area code)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02.
Results of Operations and Financial Condition
On May 15, 2017, Threshold
Pharmaceuticals, Inc. issued a press release regarding its financial results for the first quarter ended March 31, 2017. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The press release
contains statements intended as “forward-looking statements” which are subject to the cautionary statements about forward-looking
statements set forth therein.
The information furnished
pursuant to this Item 2.02 (including Exhibit 99.1 hereto) shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that Section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or the Securities Act. The information contained herein
and in the accompanying exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act or
the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits
Exhibits
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release of Threshold Pharmaceuticals, Inc. dated May 15, 2017 regarding its financial results for the first quarter ended March 31, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Threshold Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
/
s
/
Joel A. Fernandes
|
|
|
Name:
|
Joel A. Fernandes
|
|
|
Title:
|
Senior Vice President, Finance and Controller
|
Date: May 15, 2017
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release of Threshold Pharmaceuticals, Inc. dated May 15, 2017 regarding its financial results for the first quarter ended March 31, 2017.
|
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From May 2023 to May 2024